Sponsor: MUSC
Sponsor Study ID: 104060
Study Title: Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients at Risk for Cardiotoxicity (NeoCARD): A Single-arm Phase 2 Trial with a Special Focus on African American and Underserved Patients from NCORP-MU Sites
CTO #: 104060
NCT Number: NCT06845319
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: To determine the pathologic complete response (pCR) rate in TNBC patients treated with the 12-18 week CPP regimen. To evaluate radiologic response rate (RRR) at 12-week MRI defined by complete response and partial response.